SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing novel cancer therapies, led by galinpepimut-S (GPS), an off-the-shelf immunotherapeutic cancer vaccine targeting the WT1 antigen, and tambiciclib (SLS009), a selective CDK9 inhibitor. The stock last traded at $19.73, up $12.26, or 164.12%, from the prior session's close of $7.47. The direction of the move is unambiguously higher, and the reason is not in dispute: before the opening bell, the company reported positive topline results from its pivotal Phase 3 REGAL trial, which met its primary endpoint and showed a survival benefit large enough to reset the entire investment case.
The REGAL trial tested GPS as maintenance monotherapy in patients with acute myeloid leukemia (AML) who reached a second or later complete remission after salvage therapy but who were ineligible for, or unable to undergo, an allogeneic stem cell transplant — a group with historically dismal outcomes and no approved standard of care.
The results cleared the bar decisively. GPS produced a median overall survival of 24.0 months versus 14.7 months for investigators' choice of best available treatment, a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The safety profile was consistent with prior experience, with no new signals and mostly grade 1/2 local injection-site reactions. Critically, the vaccine beat physician-selected combination regimens as a single agent, which is the detail that drove the market reaction: it suggests the WT1-directed platform is validated at Phase 3, not merely tolerated.
Management said it will meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy, with preparations advancing toward a Biologics License Application submission for GPS in the first half of 2027. For a company with a modest revenue base and a development-stage profile, a credible, dated path to a first commercial approval is the single largest value inflection available, and it arrived ahead of expectations.
The readout also sharpened the outlook for SLS009. Forty patients have enrolled in the Phase 2 study in newly diagnosed AML, with preliminary data expected before year-end, and additional relapse/refractory AML findings are slated for presentation at the American Society of Hematology meeting in December. Prior investigator-led work reported response rates in specific molecular subgroups. Bulls are now valuing two de-risked assets rather than a binary bet on one trial.
This was not a sympathy trade. The iShares Biotechnology ETF (IBB) slipped about 0.7% and the SPDR S&P Biotech ETF (XBI) eased 0.3%, while the broad market and small caps also traded modestly lower. SELLAS rose against all of them, which underlines the idiosyncratic nature of the move.
Volume was extraordinarily heavy, with turnover in the opening minutes already running at many multiples of the roughly four million shares the stock typically trades in a full session. Technically, the gap higher blew through the prior 52-week high near $15.88 and reclaimed every major moving average in a single session, reversing a downtrend that had taken the shares from $12.41 in mid-October to $7.47 on Monday. Such a violent re-rating leaves little nearby resistance from recent trading, but it also leaves a large unfilled gap behind.
The score runs from 0, meaning no meaningful news and a move that is ordinary for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 96 out of 100.
The verified news is about as material as it gets for a company of this size: a pivotal Phase 3 trial met its primary survival endpoint with statistical significance and set up a 2027 filing, an outcome that collapses years of clinical and financing risk. The price response was equally extreme — roughly 37 times the stock's average daily move over the past 79 sessions and larger than any of them, none of which exceeded 16%. Strong fundamentals and unusual trading combine into a near-maximum reading.
The near-term agenda is regulatory and scientific. Investors will await details of the FDA meeting, the full REGAL dataset including secondary endpoints and subgroup analyses at an upcoming medical conference, and peer-reviewed publication. SLS009 remains the second catalyst: topline Phase 2 data in newly diagnosed AML are due before year-end, with ASH 2026 presentations in December.
Financially, the company ended September with $134.7 million in cash after a third-quarter net loss of $10.1 million, giving it runway into key milestones but also leaving it dependent on capital markets for a commercial launch build-out. Analyst coverage remains constructive, with at least one Buy rating and a target that today's price is closing in on — a reminder that the easy re-rating may already be partly captured. Risks include a narrower-than-hoped label, accelerated approval hurdles, dilution, and the tendency of catalyst-driven biotech rallies to retrace once the initial scramble fades.
Tickeron's Trending AI Robots page curates the best-performing automated strategies under present market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Each bot differs by strategy, timeframe, performance metrics, and the symbols it trades, so results vary widely across market regimes. The page surfaces only those currently standing out, making it a practical starting point for comparing approaches side by side. Visit the curated list to see which strategies are leading right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for SLS moved into overbought territory on November 17, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 37 of 42 cases over the following month. The odds of a continued upward trend are 88%.
SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals
Industry Biotechnology